About
US

Finding lifesaving medicines is a life’s work – the work of 140,000 researchers who never say never. As well as the millions of patients who fight side by side with researchers in the battle for life, against whatever odds they face together.

Now is the time to put the accelerator to the floor. The best is yet to come – like advancements in personalized medicine and immunotherapy – and it’s coming faster than we can imagine.

Welcome to the future of medicine. Where disease is no match for tenacity. No match for ingenuity. Where together, we go boldly.

DO NOT GO GENTLE

Today's breakthroughs are becoming tomorrow's medicines.

Watch the Video
Our
MEMBER COMPANIES

PhRMA member companies invest billions in the research and develop of new medicines. They are pioneers in innovation, ushering in a new era of treatment for patients. Here are our member companies:

HELPING DIABETES PATIENTS THRIVE

HELPING DIABETES PATIENTS THRIVE

Diabetes is a serious condition that effects more than 30 million Americans. While complications of the disease can be dire, there is hope. Biopharmaceutical researchers are helping patients manage the condition today and envision a bright outlook for future treatments.

Diabetes: the patient perspective

Diabetes is a general term for a chronic condition where there is too much glucose (sugar) in the blood. Normally, the pancreas makes insulin to help convert glucose into energy. With diabetes, the body either does not make enough insulin (type 1 diabetes) or does not use it properly (type 2 diabetes), leading to high blood glucose levels. Uncontrolled diabetes can lead to serious health complications, such as heart attack, lower-limb amputation, vision impairment and blindness.

Endocrinologist Dr. William "Bill" Chin has experience treating endocrine disorders, including diabetes. As chief medical officer at PhRMA, he works to ensure that patient voices are heard, drawing on his dual experience as a physician and as the parent of a child with diabetes. When Dr. Chin's son, Danny, was 15, he began experiencing telltale symptoms like excessive thirst. Dr. Chin diagnosed his son himself with type 1 diabetes.

He says, "I don’t think any parent is ever prepared to learn that one of our kids has developed a disease, particularly one that will be chronic. In many ways it’s forever, but the good news is we have great therapies that actually will allow a patient with diabetes to live a full and completely normal life if it’s well managed."

The changing landscape of diabetes treatment

The medications that Danny relies on have come a long way in the last ten years. A decade ago, a number of insulin options were available to patients, as well as oral and injected medications. Successful management of diabetes required constant and diligent monitoring of glucose levels. To control their glucose, patients needed multiple daily injections and/or multiple oral medicines.

In recent years, researchers have focused on making treatments much easier for patients, from fewer pills to less frequent injections. Careful monitoring and treatment are still needed, but current medicines in development offer a promising future.

There are 171 medicines currently in development for type 1 and type 2 diabetes and diabetes-related conditions. A new wave of treatments is offering patients better or more sustained control over their glucose levels. Other medicines in the pipeline may address diabetes-related complications that affect the kidneys, blood vessels and eyes. All of the medicines are in clinical trials or awaiting review by the FDA.

While these advances have improved patient quality of life and increased lifespans for type 1 diabetes, ongoing research remains critical. In fact, diabetes was the seventh leading cause of death in the United States in 2013.

Dr. Chin says, "Collaboration is incredibly important in the understanding and development of new treatments for diabetes ... we are continually seeking to advance our understanding of the disease. This can only be achieved by having academic scientists and physician scientists working closely with scientists in the biopharmaceutical industry."

For more information, download the PhRMA report.

PhRMA Icon